Try one of the below options to narrow down your search.
 |
Documents may be browsed by date, eg; Today, May, 2013.
Past years can be browsed too, eg; 2012, 2011, 2010, 2009 ...
Documents can be searched within a period by browsing to the date and then using the search form; or by direct links, eg; Media releases from 2013
Document tags (shown below the document date, eg; Schedule, SAForms, consultation ...) have highest priority when search results are ranked, followed by title, abstract and full text of document.
Parentheses and the keywords and, or and not have special meaning in search terms. And is implicit and can be omitted; or must be specified.
Remember to group or statements with parentheses if they are beside and statements.
Search examples
- consultation
- Search for consultations
- media and not antibiotics
- Search for media related documents that don't mention antibiotics.
- (media or consultation) and vaccines
- Search for media releases and consultation documents mentioning vaccinations.
Search term:
2007 / 04 / 13
PHARMAC documents that matched your search:
Appendix One: Relevant minutes of clinical advisory committees meetings since mid 2006
(8 pages, 164 KB)
2007/04/13
PTAC further considered trastuzumab in August 2006, and then the cancer treatments subcommittee of PTAC (CaTSoP) considered the FinHer study in November 2006. Subsequently PTAC have discussed this…
Appendix Six: Clinical data
(14 pages, 511 KB)
2007/04/13
1. Efficacy of sequential and concurrent treatments Key to graphic: Ö statistically significant improvement in disease-free survival (DFS) ´ no statistically significant improvement in DFS ? results awaited 2. Treatment regimens and available trial data To…
Appendix Two: Rapid update of TAR 75 for HERA 23 month follow-up information
(2 pages, 124 KB)
2007/04/13
Updated Clinical Information – 12 months trastuzumab sequential regimen The cost-utility analysis for 12 months sequential trastuzumab treatment has not been updated to include the new evidence…
Comparison of eligible patient pool and treatment regimen 12 months sequential treatment
(3 pages, 63 KB)
2007/04/13
Eligible patient population 9 weeks concurrent treatment Eligible patients were those presenting with HER-2 positive early breast cancer, with acceptable heart function (assumes some patients excluded from treatment…
Technology Assessment Report No. 75, with supplementary analysis 75b
(66 pages, 566 KB)
2007/04/13
Trastuzumab (Herceptin) in HER-2 positive early stage primary breast cancer Part 1: 12-month sequential trastuzumab treatment (“Trastuzumab (Herceptin) in HER-2 positive early breast cancer ”), August 2006 Part 2: 9 week…
